Current Report Filing (8-k)
03 April 2023 - 11:28PM
Edgar (US Regulatory)
0001624326
false
0001624326
2023-03-31
2023-03-31
0001624326
PAVM:CommonStockParValue0.001PerShareMember
2023-03-31
2023-03-31
0001624326
PAVM:SeriesZWarrantsToPurchaseCommonStockMember
2023-03-31
2023-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 31, 2023
PAVMED
INC. |
(Exact
Name of Registrant as Specified in Charter) |
Delaware |
|
001-37685 |
|
47-1214177 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
360
Madison Avenue, 25th
Floor, New York, New York |
|
10017 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (212) 949-4319
N/A |
(Former Name or Former Address,
if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, Par Value
$0.001 Per Share |
|
PAVM |
|
The Nasdaq Stock Market
LLC |
Series Z Warrants to Purchase
Common Stock |
|
PAVMZ |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
On
March 31, 2023, Lucid Diagnostics Inc. (“Lucid”), a majority owned subsidiary of PAVmed Inc. (the “Company”),
issued a press release announcing that, on March 30, 2023, the MolDX Program published a Future Effective Local Coverage Determination
L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023. A copy
of the press release is incorporated by reference as Exhibit 99.1 to this report and is incorporated herein by reference.
The
information furnished under Item 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the
Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01. Financial Statements and Exhibits.
(1) |
Incorporated by reference to Exhibit
99.1 to Lucid’s Form 8-K filed on April 3, 2023. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: April 3, 2023 |
PAVMED INC. |
|
|
|
|
By: |
/s/ Dennis
McGrath |
|
|
Dennis McGrath |
|
|
President and Chief Financial Officer |
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Oct 2024 to Nov 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about PAVmed Inc (NASDAQ): 0 recent articles
More Pavmed Inc. News Articles